fda reversal on knockoff glp 1 Novo Nordisk drops lawsuit against Hims & Hers over off-brand weight loss medications, enter collaboration Designing GLP-1 delivery: structural perspectives

L cells express TNF receptor 1 (TNFR1) and chronic exposure to TNF was shown to impair GLP-1 (95) as well as GLP-2 secretion (96)

J.SattarN.HornD

Plaintiffs claim manufacturers: Knew or should have known gastroparesis could be permanent Failed to adequately warn patients and doctors Understated the severity and duration of risk Continued aggressive marketing despite safety signals 2

For tirzepatide (Zepbound) Jastreboff and colleagues reported in the New England Journal of Medicine in 2022 that at maximal doses, the percent of individuals reporting side effects were as follows: Nausea 31.0% Diarrhea 23.0% Vomiting 12.2% Constipation 11.7% Bettge and colleagues conducted a study published in Diabetes, Obesity, and Metabolism in 2017 that showed that individuals who were taking metformin while taking a GLP-1 were more likely to have side effects, especially nausea and vomiting

GLP-1R predominantly signals through the G/cAMP pathway [7]

Young: And they found that quitting a GLP-1 drug, you regain that weight and you lose those health benefits much faster than those other means of weight loss